Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5fe2o3.9h2o
2. Ferric Hydroxide Oxide
3. Ferric Hydroxide Oxide (feooh)
4. Ferric Oxy-hydroxide
5. Ferric Oxyhydroxide (feo2h)
6. Ferrihydrite
7. Iron(iii) Oxyhydroxide
1. Iron(3+);oxygen(2-);hydroxide
2. Ferric Oxy-hydroxide
3. Ferric Hydroxide [mi]
4. Dtxsid3042057
5. Ferric Oxyhydroxide (feo2h)
6. Ferric Hydroxide Oxide (feooh)
7. Db14695
1. Feojectin
2. Ferplex Ss
3. Ferrivenin
4. Iviron
5. Proferrin
6. Sucrofer
7. Iron Sugar
8. Saccharated Iron
9. Venoferrum
10. Fesin
11. Ferrum Vitis
12. Hippiron
13. Ferum Hausmann
Molecular Weight | 88.85 g/mol |
---|---|
Molecular Formula | FeHO2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 88.932590 g/mol |
Monoisotopic Mass | 88.932590 g/mol |
Topological Polar Surface Area | 2 Ų |
Heavy Atom Count | 3 |
Formal Charge | 0 |
Complexity | 0 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
2 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2016-08-04
Pay. Date : 2016-07-14
DMF Number : 28865
Submission : 2016-07-07
Status : Active
Type : II
SNJ Labs: WHO-GMP certified API leader in India, specializing in bulk drugs & intermediates with unmatched expertise.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34357
Submission : 2019-12-10
Status : Active
Type : II
SNJ Labs: WHO-GMP certified API leader in India, specializing in bulk drugs & intermediates with unmatched expertise.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30380
Submission : 2016-01-03
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-10
Pay. Date : 2023-09-28
DMF Number : 38610
Submission : 2023-07-31
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34957
Submission : 2020-06-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33643
Submission : 2019-03-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18261
Submission : 2005-04-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18015
Submission : 2005-01-12
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-31
Pay. Date : 2013-01-09
DMF Number : 18390
Submission : 2005-05-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-03-17
Pay. Date : 2022-03-14
DMF Number : 19544
Submission : 2006-06-26
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, under evaluation to reduce post-operative complications.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2025
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Completes Enrollment in Phase 3 PROTECT Trial of RBT-1 for Cardiac Surgery
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, under evaluation to reduce post-operative complications.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2025
Details:
RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2024
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Announces Publication Of Results from Phase 2 Study Evaluating RBT-1
Details : RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2024
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 25, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surg...
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2023
Details:
The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 18, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $47.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surg...
Product Name : RBT-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2023
Details:
Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Brand Name: Velphoro
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
VFMCRP Announces U.S. Court Upholds Validity of Velphoro® Patent
Details : Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Product Name : Velphoro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Details:
Clinical Kidney Journal published results from a real-world setting study, the VELREAL multicenter study, which showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level using Vifor Pharma’s Velphoro in CKD patients on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Brand Name: Velphoro
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2021
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Real-World Setting Study Shows Velphoro Effective in CKD-HP Management
Details : Clinical Kidney Journal published results from a real-world setting study, the VELREAL multicenter study, which showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level using Vifor Pharma’s Velphoro in CKD patients on ...
Product Name : Velphoro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2021
Details:
Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2020
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association
Details : Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Details:
The company launched generic version of sucroferric oxyhydroxide tablets, indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Brand Name: Dynulta
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2020
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Emcure Pharma Launches Generic Drug for Hyperphosphatemia in Chronic Kidney Disease Patients
Details : The company launched generic version of sucroferric oxyhydroxide tablets, indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Product Name : Dynulta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2020
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Iron Sucrose API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Iron Sucrose manufacturer or Iron Sucrose supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Iron Sucrose manufacturer or Iron Sucrose supplier.
PharmaCompass also assists you with knowing the Iron Sucrose API Price utilized in the formulation of products. Iron Sucrose API Price is not always fixed or binding as the Iron Sucrose Price is obtained through a variety of data sources. The Iron Sucrose Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ferric oxyhydroxide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ferric oxyhydroxide, including repackagers and relabelers. The FDA regulates Ferric oxyhydroxide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ferric oxyhydroxide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ferric oxyhydroxide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ferric oxyhydroxide supplier is an individual or a company that provides Ferric oxyhydroxide active pharmaceutical ingredient (API) or Ferric oxyhydroxide finished formulations upon request. The Ferric oxyhydroxide suppliers may include Ferric oxyhydroxide API manufacturers, exporters, distributors and traders.
click here to find a list of Ferric oxyhydroxide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ferric oxyhydroxide DMF (Drug Master File) is a document detailing the whole manufacturing process of Ferric oxyhydroxide active pharmaceutical ingredient (API) in detail. Different forms of Ferric oxyhydroxide DMFs exist exist since differing nations have different regulations, such as Ferric oxyhydroxide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ferric oxyhydroxide DMF submitted to regulatory agencies in the US is known as a USDMF. Ferric oxyhydroxide USDMF includes data on Ferric oxyhydroxide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ferric oxyhydroxide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ferric oxyhydroxide suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ferric oxyhydroxide Drug Master File in Korea (Ferric oxyhydroxide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ferric oxyhydroxide. The MFDS reviews the Ferric oxyhydroxide KDMF as part of the drug registration process and uses the information provided in the Ferric oxyhydroxide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ferric oxyhydroxide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ferric oxyhydroxide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ferric oxyhydroxide suppliers with KDMF on PharmaCompass.
A Ferric oxyhydroxide written confirmation (Ferric oxyhydroxide WC) is an official document issued by a regulatory agency to a Ferric oxyhydroxide manufacturer, verifying that the manufacturing facility of a Ferric oxyhydroxide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ferric oxyhydroxide APIs or Ferric oxyhydroxide finished pharmaceutical products to another nation, regulatory agencies frequently require a Ferric oxyhydroxide WC (written confirmation) as part of the regulatory process.
click here to find a list of Ferric oxyhydroxide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ferric oxyhydroxide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ferric oxyhydroxide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ferric oxyhydroxide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ferric oxyhydroxide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ferric oxyhydroxide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ferric oxyhydroxide suppliers with NDC on PharmaCompass.
Ferric oxyhydroxide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ferric oxyhydroxide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ferric oxyhydroxide GMP manufacturer or Ferric oxyhydroxide GMP API supplier for your needs.
A Ferric oxyhydroxide CoA (Certificate of Analysis) is a formal document that attests to Ferric oxyhydroxide's compliance with Ferric oxyhydroxide specifications and serves as a tool for batch-level quality control.
Ferric oxyhydroxide CoA mostly includes findings from lab analyses of a specific batch. For each Ferric oxyhydroxide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ferric oxyhydroxide may be tested according to a variety of international standards, such as European Pharmacopoeia (Ferric oxyhydroxide EP), Ferric oxyhydroxide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ferric oxyhydroxide USP).